Promising results have been recently documented by oral Met supplementation in four children with PAP and multisystemic dysfunction related to MARS1 mutations with full remission of the disease in two patients and a clear ongoing improvement in the two others [6]. This evidence concerns the gene MARS1 and pulmonary alveolar proteinosis.